fastGEN - Next Generation Sequencing

Personalised therapy can provide an opportunity for patients with various types of cancer to prolong and improve their quality of life. Knowledge about the mutation status of KRAS, NRAS, BRAF, EGFR, H3F3A, IDH 1/2, POLE/CTNNB1, BCR::ABL1 etc. genes is required to indicate the proper treatment of metastatic carcinomas and to assess the disease prognosis. BioVendor developed user friendly diagnostic NGS kits with excellent analytical parameters and extremely fast processing for laboratories of any size. The fastGEN technology is simple, ultra-sensitive, specific and effective - it is perfectly adapted to diagnostics. With ready-to-use reagents, a user-friendly workflow and all-in-one solution for the analysis of raw data offers fastGEN technology new advantages for clinical material.